Pfizer Regenerative Medicine, Cambridge, UK.
Cell Stem Cell. 2010 Jun 4;6(6):517-20. doi: 10.1016/j.stem.2010.05.012.
Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corporate strategies.
人类干细胞生物学正在推动新型再生疗法的承诺进入临床试验。尽管制药行业已经将干细胞作为药物发现的工具，但很少有公司敢于冒险提供基于干细胞的药物。在这里，我们评估了各种基于细胞的机会和公司策略。
